London, July 1, 2026, 22:06 BST
- Haleon ended at 350.50 pence, gaining 0.81%. The FTSE 100 slipped 0.18%.
- New filings show Haleon voting shares now at 8.809 billion, a drop of 4.6% since the 2022 admission figure.
- Haleon’s H1 aide-memoire said around 86% of its 500 million pound 2026 buyback was done by June 18, with later trades adding about 23 million pounds.
- Near-term support for the stock remains linked to cash returns and productivity. Q1 volume/mix fell 0.2%.
Haleon PLC (LON:HLN) gained on Wednesday as the FTSE 100 traded lower. Traders focused on Haleon’s buyback, with the share count dropping quickly. It looks like the bulk of this year’s cash return is already spent before first-half results come out.
Haleon ended the day at 350.50 pence, up 2.80 pence, or 0.81%. Trading volume was 22.6 million shares, with on-book turnover at about 65.6 million pounds, according to London Stock Exchange data. The FTSE 100 dropped 18.78 points, or 0.18%, to 10,478.34.
| Market measure | July 1 close | Day change |
|---|---|---|
| Haleon (LON:HLN) | 350.50p | up 0.81% |
| FTSE 100 | 10,478.34 | down 0.18% |
| Haleon volume | 22.6 mln shares | — |
| Haleon on-book turnover | £65.6 mln | — |
The daily move wasn’t what mattered most for holders. Haleon’s Wednesday filing showed ordinary shares with voting rights at 8,808,899,708, after removing 12,006,714 treasury shares. When Haleon started trading in July 2022, it had 9,234,573,831 ordinary shares with one vote each. That means the voting base has dropped by about 425.7 million shares, or 4.6%, according to Reuters-style numbers.
| Disclosure point | Voting shares | Change vs admission |
|---|---|---|
| July 2022 admission | 9.2346 bln | — |
| June 1, 2026, after late-May buyback settles | 8.8473 bln | -4.2% |
| June 22, 2026, after June 16-18 buybacks | 8.8159 bln | -4.5% |
| July 1, 2026, voting-rights update | 8.8089 bln | -4.6% |
Haleon’s latest disclosure shows it bought 6,992,435 shares for cancellation on June 22 and June 23. The average price was 333.13p, based on data by trading venue in the filing. That works out to around £23.3 million in total. The buyback price is roughly 5.2% under Wednesday’s close.
The H1 2026 aide-memoire from the company noted that as of June 18, around 86% of the 500 million pound buyback was done. Taking that at face value, the June 22-23 buys would push the total to about 453 million pounds—roughly 91% of the full-year amount—before half-year results hit on July 30.
Investors are still waiting for Haleon to deliver faster sales. Organic revenue for Q1 rose 2.2%—prices climbed 2.4% but volume and mix dropped 0.2%. The company blamed a weak cold and flu season for about 130 basis points of pressure. Oral Health posted 8.3% growth, while Respiratory Health was down 3.4%, and Pain Relief slipped 0.3%. CEO Brian McNamara told investors in April that Haleon sees growth picking up “across the balance of the year.” Haleon Corporate
| Q1 2026 measure | Organic growth |
|---|---|
| Haleon total | up 2.2% |
| Oral Health | rose 8.3% |
| VMS | added 1.7% |
| Pain Relief | off 0.3% |
| Respiratory Health | fell 3.4% |
A second filing focused on productivity, not revenue. Haleon said on June 29 it had entered a five-year deal with Microsoft Corporation NASDAQ:MSFT to bring more AI, data, and cloud capabilities to its consumer insights, supply chain, research, marketing and commercial operations. Claire Dickson, Haleon’s chief digital and tech officer, said the collaboration targets “driving growth” and stronger productivity. Microsoft UK and Ireland CEO Darren Hardman said Haleon was acting with “real pace and purpose.” Haleon Corporate
The stock is getting tugged by two things right now: a smaller share count that’s helping earnings per share, and a sales base that needs more volume. Results out July 30 will show if Oral Health is still doing the heavy lifting as North America and cold-and-flu sales try to rebound.
